All issues > Volume 57(8); 2014

Case Report

Published online: August 25, 2014

DOI: https://doi.org/10.3345/kjp.2014.57.8.374

A pediatric case of Brugada syndrome diagnosed by fever-provoked ventricular tachycardia

Geena Kim, MD¹, Ye-Chan Kyung, MD², I-Seok Kang, MD², Jinyoung Song, MD, PhD², June Huh, MD, PhD², Young Keun On, MD, PhD³

¹Department of Pediatrics, Pusan National University Children's Hospital, Pusan National University School of Medicine, Yangsan, Korea.

²Division of Cardiology, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

³Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.

Corresponding author: June Huh, MD, PhD. Department of Pediatrics, Samsung Medical Center, Cardiac and Vascular Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-3526, Fax: +82-2-3410-0043, herzhuh@skku.edu

Received July 04, 2013       Revised September 09, 2013       Accepted October 13, 2013

Copyright © 2014 by The Korean Pediatric Society

(open-access, http://creativecommons.org/licenses/by-nc/3.0/):

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Brugada syndrome is a rare channelopathy associated with the SCN5A gene that causes fatal ventricular arrhythmias. This case of Brugada syndrome, in which ventricular tachycardia (VT) was provoked by high fever, is the first report in a Korean child. The boy had retinoblastoma of his left eye diagnosed at 16 months of age. After chemotherapy, he contracted a catheter-related infection with a high fever up to 41℃ leading to monomorphic VT. This was characterized as having right bundle branch block morphology, superior axis deviation, and a heart rate of 212/min. Direct current cardioversion recovered the VT to sinus rhythm after a lack of response to amiodarone and lidocaine. A second attack of VT that was not controlled by cardioversion, however, responded to lidocaine. The baseline electrocardiogram showed a long PR interval and QRS duration, and the patient's grandfather had a history of Brugada syndrome. A mutation in SCN5A was identified in this patient, his father, and his grandfather. The patient was treated with quinidine and followed up for 1 year.

Key words: Brugada syndrome, Fever, Ventricular tachycardia, Child, Retinoblastoma

Introduction

Introduction

Brugada syndrome (BrS) is recognized as an important cause of sudden cardiac death (SCD) occurring in individuals at a relatively young age. BrS is an inherited cardiac arrhythmia condition, characterized by coved ST elevation and J point elevation of at least 2 mm in at least two of the right precordial electrocardiogram (ECG) leads (V1-3)¹⁾. It is a familial condition that displays an autosomal dominant mode of transmission. In the majority of patients, BrS is caused by mutations in the cardiac sodium channel gene SCN5A, which encodes the α-subunit of the sodium channel. There are fewer reports of pediatric BrS than adult because BrS usually develops as arrhythmia in adulthood.

Case report

Case report

The boy presented with a white pupil in his left eye and was diagnosed with retinoblastoma in the left eye at 16 months of age. He was placed on retinoblastoma chemotherapy protocol 2005 for 4 months and his left eyeball was enucleated. At 26 months of age, the boy suffered a high fever and was brought to our emergency department on the 4th day after fever developed. His vital signs in the Emergency Department were blood pressure 94/56 mmHg, heart rate 134 beats/min and temperature 37.5℃. The physical examination found no specific cause of the fever. As the patient still had a central line for chemotherapy, a catheter-related infection was initially suspected, so blood cultures were taken and empirical antibiotics was given.

The baseline ECG showed a first-degree atrioventricular (AV) block with a PR interval of 268 ms and a QRS duration of 103 ms (Fig. 1). The echocardiographic findings were normal. On the 5th day of fever, his body temperature measured by tympanic thermometer was 41℃. The boy suddenly developed monomorphic wide QRS tachycardia, which was characterized as having right bundle branch block (RBBB) morphology with a QRS duration of 200 ms, superior axis deviation, and a tachycardia rate of 212/min (Fig. 2). The boy was alert and his blood pressure was stable at 87/45 mmHg. At first, the boy did not respond to adenosine treatment for wide QRS tachycardia; this was followed by amiodarone and lidocaine, but the wide QRS tachycardia was not corrected. After the failure of amiodarone and lidocaine, direct current (DC) cardioversion (1 J/kg) succeeded in recovering the patient's rhythm to sinus rhythm. The wide QRS tachycardia was diagnosed as ventricular tachycardia (VT) of unknown origin but related to high fever. Next day, the patient presented with fever up to 38.8℃ and VT occurred again. This second attack of VT did not respond to DC cardioversion, but responded to lidocaine. On the ECG, a transient Brugada pattern was observed shortly after DC cardioversion. Blood culture was positive for methicillin-sensitive Staphylococcus aureus, leading to a diagnosis of catheter-related infection. The boy was treated with nafcillin and cefazolin for 6 weeks. Investigation of his family history found that his grandfather was diagnosed as BrS because of frequent syncopal attacks (Fig. 3), had been taking quinidine, and had recently undergone insertion of an implantable cardioverter-defibrillator (ICD) because of his frequent syncopal attacks. The father also showed conduction delay with a PR interval of 204 ms and a QRS duration of 136 ms (Fig. 3), but had not experienced any episodes of VT. Gene analysis by direct sequencing of genomic DNA isolated from peripheral blood leukocytes revealed a mutation in the SCN5A gene in the patient, his father, and his grandfather, that was identified as a C to T base substitution at nucleotide position 3911 leading to replacement of threonine with methionine at codon 1304 (c.3911C>T, p.T1304M). The patient's elder sister and his mother had a normal ECG and no identified genetic mutation. The patient was treated with quinidine for 9 months, until the patient's parents stopped the treatment against medical advice. Fortunately, the boy had no more episodes of high fever causing VT, and we educated the parents about the need for the boy to be given antipyretics at the first sign of fever. There have been no more episodes of VT during 1 year of outpatient clinic follow-up.

Discussion

Discussion

Brugada syndrome can be classified into 3 types according to ECG characteristics. A type 1 ECG pattern is characterized by a coved ST-segment elevation greater than or equal to 2 mm and is followed by a negative T wave in more than 1 right precordial lead (V1-V3). A type 2 ECG pattern is characterized by gradually descending ST-segment elevation that results in a saddleback morphology. A type 3 ECG pattern is characterized by ST-segment elevation less than or equal to 1 mm with either a coved type or a saddleback morphology. Diagnosis of BrS is based on the appearance of a type 1 ST-segment elevation (coved type) in more than one right precordial lead (V1-V3), in the presence or absence of a sodium channel blocker, and any one of the following suggests BrS: ventricular fibrillation, VT, a family history of SCD (aged <45 years), coved type ECGs in family members, electrophysiological inducibility, and syncope or nocturnal agonal respiration²⁾. Since BrS was first identified by Brugada and Brugada¹⁾ in 1992, many cases have been reported in adults and children3,⁴⁾. The prevalence of BrS in children has not been precisely determined because of its clinical spectrum that can range from asymptomatic to sudden death³⁾. BrS symptoms in childhood are frequently associated with fever. Probst et al.³⁾ showed that episodes of syncope were associated with fever in 5 of 11 cases (45%). Four of 5 patients had documented arrhythmia, polymorphic VT or monomorphic VT and atrial flutter. Three of 5 patients had a family history of BrS. Zaidi⁵⁾ described a 10-year-old boy with a family history of SCD who had near syncope associated with a febrile illness, and De Marco et al.⁶⁾ reported a 4-year-old boy who, while feverish, showed coved ST-segment elevation in the right precordial leads and incomplete RBBB.

The role of fever as a precipitating factor for ventricular arrhythmias in BrS has been described in previous reports⁷⁾. It has been reported that mutations leading to BrS affect the temperature sensitivity of the rapid inactivation of the sodium channel⁸⁾. One of the theories explaining the ECG alterations seen in BrS with fever is based on an imbalance between the depolarizing and repolarizing currents during the early repolarization phase of the action potential, mainly demonstrated by a large transient outward current in the epicardial cells of the right ventricle⁸⁾. However, the exact mechanism of this effect has not yet been clearly shown.

The important consideration is that as fever is the state most likely to induce ventricular arrhythmia in childhood BrS, we need a careful evaluation of this situation, and antipyretics should be used liberally in these patients.

Genetic mutations are identified in only 20%-30% of patients with BrS and all identified mutations involve the SCN5A gene⁷⁾. The relationship between gene mutation and fever is uncertain. Keller et al.⁹⁾ investigated the heterogeneous genetic background of BrS and the relationship between clinical manifestations of fever-induced BrS and different mutations. There was no association between clinical manifestations and any specific mutation. Meregalli et al.¹⁰⁾ reported a relationship between the type of mutation and the severity and conduction delay in loss-of-function SCN5A channelopathies: patients carrying T and M_inactive mutations had significantly longer PR and QRS intervals than those with M_active mutations.

Mutations in SCN5A, the gene encoding the α subunit of the most prevalent cardiac Na channel, are responsible for a spectrum of hereditary arrhythmias, including type 3 long QT syndrome, BrS, cardiac conduction disturbances, and sick sinus syndrome¹¹⁾. Our patient had a mutation, T1304M, in the D3/S4 voltage-sensing region of SCN5A. The threonine residues at position 1304 in the wild-type sodium channels are probably critical for proper sodium channel function¹²⁾. A T1304M mutation was also reported in type 3 long QT syndrome: 5 of 6 patients in that study with this mutation had syncope-like symptoms¹²⁾.

We analyzed the baseline ECG of our patient, which showed a first-degree AV block with a PR interval of 268 ms and a QRS duration of 103 ms. Chockalingam et al.¹³⁾ reported that conduction intervals such as the PR interval and the QRS duration were greater than the upper limit of normal for age in 28 (85%) BrS patients, and Kanter et al.¹⁴⁾ showed that prolonged cardiac conduction intervals have emerged as the most common manifestation of the disease in infants. Therefore, a cardiac depolarizing channel defect should be considered in patients with a structurally normal heart and fever-induced VT, and analysis of conduction delay and investigation of the family history should be performed.

Further, we need to focus on how to evaluate the risk and to stratify patients at risk for SCD, to select those patients in whom to insert an ICD. An 8% occurrence of cardiac events was observed in initially asymptomatic patients⁷⁾; hence, it is important to assess the risk of cardiac events to decide between treatment options, including medication only or ICD implantation. A risk stratification scheme has been proposed, including the presence of symptoms (aborted sudden death, syncope, seizure, nocturnal agonal respiration), spontaneous or drug-induced coved type ECG pattern and a family history of sudden death.

Quinidine therapy has been proposed as an alternative to ICD implantation in asymptomatic patients with BrS⁴⁾, and the largest reported study in children with BrS described the results of hydroquinidine medication. Four children, who were considered high risk with a spontaneous type-1 ECG, received hydroquinidine and did not have any symptoms over a 28-month follow-up³⁾. However, the recommendation of prophylactic quinidine therapy is still controversial, especially in children, as its use in children is limited and not well documented. However, in our case, we used quinidine because the patient was considered high risk for SCD and was too young for the insertion of an ICD. For symptomatic patients who experience cardiac arrest or unexplained syncope, implantation of an ICD is currently the only proven effective therapy. However, ICD implantation in childhood has high morbidity, and patients require ICD replacement. Some reports have shown that quinidine prevents induction of ventricular fibrillation in high-risk patients with BrS¹⁵⁾.

We believe that this is the first report of a pediatric case of BrS in a Korean child in which VT was provoked by high fever and a family history was present. Pediatricians should be cognizant of the possibility of BrS, especially in patients with conduction delay on baseline ECG who have a family history of sudden death and unexplained syncope.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

References

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391–1396.
[Article] [PubMed]

2. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002;106:2514–2519.
[Article] [PubMed]

3. Probst V, Denjoy I, Meregalli PG, Amirault JC, Sacher F, Mansourati J, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007;115:2042–2048.
[Article] [PubMed]

4. Probst V, Evain S, Gournay V, Marie A, Schott JJ, Boisseau P, et al. Monomorphic ventricular tachycardia due to Brugada syndrome successfully treated by hydroquinidine therapy in a 3-year-old child. J Cardiovasc Electrophysiol 2006;17:97–100.
[Article] [PubMed]

5. Zaidi AN. An unusual case of Brugada syndrome in a 10-year-old child with fevers. Congenit Heart Dis 2010;5:594–598.
[Article] [PubMed]

6. De Marco S, Giannini C, Chiavaroli V, De Leonibus C, Chiarelli F, Mohn A. Brugada syndrome unmasked by febrile illness in an asymptomatic child. J Pediatr 2012;161:769–769.e1.
[Article] [PubMed]

7. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2005;2:429–440.
[Article] [PubMed]

8. Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko VV, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999;85:803–809.
[Article] [PubMed]

9. Keller DI, Rougier JS, Kucera JP, Benammar N, Fressart V, Guicheney P, et al. Brugada syndrome and fever: genetic and molecular characterization of patients carrying SCN5A mutations. Cardiovasc Res 2005;67:510–519.
[Article] [PubMed]

10. Meregalli PG, Tan HL, Probst V, Koopmann TT, Tanck MW, Bhuiyan ZA, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 2009;6:341–348.
[Article] [PubMed]

11. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 2008;118:2219–2229.
[PubMed] [PMC]

12. Wattanasirichaigoon D, Vesely MR, Duggal P, Levine JC, Blume ED, Wolff GS, et al. Sodium channel abnormalities are infrequent in patients with long QT syndrome: identification of two novel SCN5A mutations. Am J Med Genet 1999;86:470–476.
[Article] [PubMed]

13. Chockalingam P, Clur SA, Breur JM, Kriebel T, Paul T, Rammeloo LA, et al. The diagnostic and therapeutic aspects of loss-of-function cardiac sodium channelopathies in children. Heart Rhythm 2012;9:1986–1992.
[Article] [PubMed]

14. Kanter RJ, Pfeiffer R, Hu D, Barajas-Martinez H, Carboni MP, Antzelevitch C. Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation 2012;125:14–22.
[Article] [PubMed]

15. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731–1737.
[Article] [PubMed]

Fig. 1

Patient's electrocardiogram in sinus rhythm, showing first-degree atrioventricular block with a PR interval of 268 ms and a QRS duration of 103 ms.

Fig. 2

Monomorphic ventricular tachycardia with fever detected in the emergency room, showing an right bundle branch block pattern and superior axis deviation.

Fig. 3

Electrocardiograms (ECGs) of the patient and his family. (A) ECG of patient showing long PR interval and prolonged QRS duration. (B) ECG of elder sister showing normal pattern. (C) ECG of father showing long PR interval. (D) ECG of grandfather showing typical features of the coved type ECG pattern of Brugada syndrome.